Revenue Gains, Bold Guidance Lift ADMA Shares

AMDA is a biopharmaceutical company that manufactures, markets, and develops specialty biologics to treat patients at risk of infection. Its plasma-derived treatments help ease the suffering of immunocompromised patients in the U.S. and around the world – and its treatments are gaining in popularity. Plus, a recent regulatory approval related to a production process enhancement is expected to deliver output gains, which should help ADMA’s overall business growth.

Financially, ADMA’s first-quarter fiscal 2025 earnings report showed big quarterly sales gains, with a 40% jump in overall revenue on a year-over-year basis, to nearly $115 million. Profits rose to $61.1 million, up from $39.1 million a year prior. Similarly, EBITDA increased 81% (to $47.9 million), and net income rose to nearly $27 million, up from almost $18 million a year ago. Also, company management increased financial guidance across the board for fiscal 2025 and 2026, indicating confidence in the overall growth strategy.

It’s no wonder ADMA shares are up 24% this year – and they could rise more. MAPsignals data shows how Big Money investors are betting heavily on the forward picture of the stock.

Big Money Buying ADMA

Institutional volumes reveal plenty. Recently, ADMA has enjoyed strong investor demand, which we believe to be institutional support.

Each green bar signals unusually large volumes in ADMA shares. They reflect our proprietary inflow signal, pushing the stock higher:

Plenty of health care names are under accumulation right now. But there’s a powerful fundamental story happening with ADMA.

ADMA Fundamental Analysis

Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, ADMA has had strong sales and earnings growth:

• 3-year sales growth rate (+74.4%)
• 3-year EPS growth rate (+48.6%)

Source: FactSet

Also, EPS is estimated to ramp higher this year by +40.4%.

Now it makes sense why the stock has been powering to new heights. ADMA has a track record of strong financial performance.

Marrying great fundamentals with our proprietary software has found some big winning stocks over the long term.

ADMA has been a top-rated stock at MAPsignals. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

It’s made the rare Top 20 report multiple times in the last year. The blue bars below show when ADMA was a top pick…making share values rise higher:

Tracking unusual volumes reveals the power of money flows.

This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.

ADMA Price Prediction

The ADMA rally isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no position in ADMA at the time of publication.

If you are a Registered Investment Advisor (RIA) or are a serious investor, take your investing to the next level, learn more about the MAPsignals process here.